Browse ACTA2

Summary
SymbolACTA2
Nameactin, alpha 2, smooth muscle, aorta
Aliases ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location10q23.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton.
Domain PF00022 Actin
Function

Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells.

> Gene Ontology
 
Biological Process GO:0001655 urogenital system development
GO:0001822 kidney development
GO:0002064 epithelial cell development
GO:0003012 muscle system process
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0006936 muscle contraction
GO:0006939 smooth muscle contraction
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0009615 response to virus
GO:0014829 vascular smooth muscle contraction
GO:0032835 glomerulus development
GO:0035150 regulation of tube size
GO:0035850 epithelial cell differentiation involved in kidney development
GO:0042310 vasoconstriction
GO:0050880 regulation of blood vessel size
GO:0060485 mesenchyme development
GO:0061005 cell differentiation involved in kidney development
GO:0061437 renal system vasculature development
GO:0061440 kidney vasculature development
GO:0061448 connective tissue development
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072007 mesangial cell differentiation
GO:0072008 glomerular mesangial cell differentiation
GO:0072012 glomerulus vasculature development
GO:0072109 glomerular mesangium development
GO:0072132 mesenchyme morphogenesis
GO:0072143 mesangial cell development
GO:0072144 glomerular mesangial cell development
GO:0090066 regulation of anatomical structure size
GO:0090130 tissue migration
GO:0090131 mesenchyme migration
GO:1904238 pericyte cell differentiation
Molecular Function -
Cellular Component GO:0015629 actin cytoskeleton
GO:0030027 lamellipodium
GO:0030175 filopodium
GO:0030485 smooth muscle contractile fiber
GO:0031252 cell leading edge
GO:0043292 contractile fiber
GO:0044297 cell body
GO:0044449 contractile fiber part
GO:0098858 actin-based cell projection
> KEGG and Reactome Pathway
 
KEGG hsa04270 Vascular smooth muscle contraction
Reactome R-HSA-397014: Muscle contraction
R-HSA-445355: Smooth Muscle Contraction
Summary
SymbolACTA2
Nameactin, alpha 2, smooth muscle, aorta
Aliases ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location10q23.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ACTA2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolACTA2
Nameactin, alpha 2, smooth muscle, aorta
Aliases ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location10q23.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ACTA2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolACTA2
Nameactin, alpha 2, smooth muscle, aorta
Aliases ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location10q23.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ACTA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9690.0392
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.2850.666
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7340.732
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5220.521
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7090.819
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.280.945
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2460.635
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0160.993
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4860.817
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1920.681
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.4890.553
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4670.0124
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ACTA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolACTA2
Nameactin, alpha 2, smooth muscle, aorta
Aliases ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location10q23.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ACTA2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolACTA2
Nameactin, alpha 2, smooth muscle, aorta
Aliases ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location10q23.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ACTA2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ACTA2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolACTA2
Nameactin, alpha 2, smooth muscle, aorta
Aliases ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location10q23.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ACTA2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolACTA2
Nameactin, alpha 2, smooth muscle, aorta
Aliases ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location10q23.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ACTA2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolACTA2
Nameactin, alpha 2, smooth muscle, aorta
Aliases ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location10q23.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ACTA2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolACTA2
Nameactin, alpha 2, smooth muscle, aorta
Aliases ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location10q23.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ACTA2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ACTA2.
ID Name Drug Type Targets #Targets
DB12695Phenethyl IsothiocyanateSmall MoleculeACTA2, ACTB, ATP5B, ATP5I, ATP5L, CYB5B, DIABLO, FBXO41, HNRNPF, H ......45